Aziyo Biologics (AZYO) received an additional $4M term loan from SWK Holdings Corporation (SWKH). The additional $4M term loan is the second tranche under an existing aggregate $25M credit facility. The initial $21M term loan under the facility was funded in August 2022. The additional debt financing follows Aziyo’s recently closed $11.2M public offering of common stock in December 2022, resulting in a combined aggregate amount of $15.2M in gross proceeds from these two financings. The Company plans to use the proceeds to expand its product development and clinical research activities, hire additional sales personnel to coincide with product launches and to fund working capital and other general corporate purposes.
Protect Your Portfolio Against Market Uncertainty
- Discover companies with rock-solid fundamentals in TipRanks' Smart Value Newsletter.
- Receive undervalued stocks, resilient to market uncertainty, delivered straight to your inbox.
Published first on TheFly
See Insiders’ Hot Stocks on TipRanks >>
Read More on AZYO:
- Aziyo Biologics Announces Funding of Additional $4 Million Term Loan with SWK Holdings Corporation
- Aziyo Biologics 2.35M share Spot Secondary priced at $4.75
- Aziyo Biologics, Inc. Announces Pricing of $11.2 Million Public Offering of Common Stock
- Aziyo Biologics $10M Spot Secondary; price range $6.90
- Aziyo Biologics announces common stock offering, no amount given